publication date: Aug. 8, 2014
It’s possible that molecular testing is doing a lot of good, pinpointing cancer therapies that are most likely (or least likely) to work.
It’s also possible that Medicare is paying for molecular tests that are marketed aggressively despite being based on flimsy evidence.
The latter picture is painted in a suit filed by two former employees of Caris Life Sciences Inc., a company that markets the “Caris Molecular Intelligence” test, a panel of assays previously called “Target Now.”
The whistleblowers allege that their former employer violated the federal anti-kickback statute by routinely waiving some of its fees to induce referrals to federal healthcare programs.
|Conversation with The Cancer Letter|
Daniel Hayes Leads Tour of Caris Website
Tumor profiling information Caris Life Sciences provides in its reports isn’t backed by sufficient evidence to justify some clinical decisions, said Daniel Hayes, a breast cancer expert at the University of Michigan.
Hayes, the university’s Stuart B. Padnos Professor of Breast Cancer Research and a member of a recent Institute of Medicine committee that issued a report on omics, was clicking through the Caris website as he spoke with Paul Goldberg, editor and publisher of The Cancer Letter.
|Caris Officials Respond To Questions Submitted By The Cancer Letter|
The Cancer Letter submitted seven questions to Caris Life Sciences regarding their suite of molecular diagnostic tests.
Questions focused on the costs of the tests, who pays for them, and how much of the information they provide is actionable.
|The Cancer Letter is taking a Summer Break|
The next issue will be published Sept. 5.
|NCI Launches NCORP with 53 Grants Totaling $465 Million|
NCI awarded 53 five-year grants for multi-site clinical trials and care delivery research studies through the NCI Community Oncology Research Program. The program will provide $93 million each year.
Emmanuel Farber, Experimental Pathologist, Dies at Age 95
Emmanuel Farber, a pathologist who made contributions to the understanding of chemical carcinogenesis, died Sunday, Aug. 3.
Peter Pisters named CEO of University Health Network in Toronto
MD Anderson and Hospital Israelita Albert Einstein form partnership
Richard Wahl named head of radiology at Washington University in St. Louis
David Espey steps down as acting director of CDC Division of Cancer Prevention and Control
Michael Bookman named medical director of US Oncology Research Gynecology Research Program
Richard David named professor of urology at UCLA
Jennifer Zeitzer named deputy director of FASEB public affairs office
Jeffrey Albers named CEO of Blueprint Medicines
Conquer Cancer Foundations names Raj Mantena and Aaron Sasson to board of directors
Dr. Susan Love Research Foundation receives NIH grant to develop low-cost, portable ultrasound
Massachusetts General Hospital receives award from American Hospital Association
Association of Community Cancer Centers launches online drug database
Bristol-Myers Squibb forms agreement with Leica Biosystems
AstraZeneca and Qiagen to collaborate on companion diagnostic
Optim Oncology and Urology Centers of Oklahoma join The US Oncology Network
FDA and EMA grant orphan designation to AbbVie’s ABT-414